CRP levels are strong, independent predictors of cardiovascular risk and can enhance risk stratification. Jupiter enrolled 17 802 apparently healthy middle-aged men and women with CRP levels over 2.0 mg/l, and LDL less than 130 mg/dl. They were randomized to receive rosuvastatin 20 mg daily or placebo, and followed for a primary endpoint of nonfatal myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death for 1.9 years. Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin was tolerated relatively well, with a small rise in physician-reported diabetes. Jupiter data suggest that patients with high levels of CRP should receive statins. Approximately 4.3% of the population satisfies Jupiter inclusion criteria. A review of the assessment of cardiovascular risk is under way at the National Institutes of Health to guide practitioners.
American Diabetes Association (2009) Standards of medical care in diabetes - 2009. Diabetes Care32(Suppl): S13-S61.
2.
Anderson, J.L. (2008) Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention . Am J Cardiol101: 23F-33F.
3.
Bhatt, D.L. (2008) Anti-inflammatory agents and antioxidants as a possible `third great wave' in cardiovascular secondary prevention. Am J Cardiol101: 4D-13D.
4.
Blumenthal, R.S., Michos, E.D. and Nasir, K. (2007) Further improvements in CHD risk prediction for women. JAMA297: 641-643.
5.
Budoff, M.J., Achenbach, S., Blumenthal, R.S., Carr, J.J., Goldin, J.G., Philip Greenland, P. et al. (2006) Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention. Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation114: 1761-1791.
6.
Capuzzi, D.M. and Freeman, J.S. (2007) C-reactive protein and cardiovascular risk in the metabolic syndrome and type 2 diabetes: controversy and challenge. Clin Diabetes25: 16-22.
7.
Cholesterol Treatment Trialists' (CTT) Collaborators (2008) Efficacy of cholesterol-lowering therapy in 18696 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet371: 117-125.
8.
Corson, M.A., Jones, P.H. and Davidson, M.H. (2008) Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker . Am J Cardiol101(Suppl.): 41F-50F.
9.
Davidson, M.H., Corson, M.A., Alberts, M.J., Anderson, J.L., Gorelick, P.B., Jones, P.H. et al. (2008) Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol101(Suppl.): 51F-57F.
10.
Everett, B.M. and Ridker, P.M. (2008) Using inflammatory biomarkers to guide lipid therapy . Curr Cardiovasc Risk Reports2: 29-34.
11.
Fruchart, J.-C., Sacks, F., Hermans, M.P., Assmann, G., Brown, W.W., Ceska, R. et al. (2008) The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia . Am J Cardiol102(Suppl.): 1K-34K.
12.
Greenland, P., Smith Jr, S.C. and Grundy, S.M. (2001) Improving coronary heart disease risk assessment in a symptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation104: 1863-1867.
13.
Greenland, P., Bonow, R.O., Brundage, B.H., Budoff, M.J., Eisenberg, M.J., Grundy, S.M. et al. (2007) ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation115: 402-426.
14.
Gustafson, B., Hammarstedt, A., Andersson, C.X. and Smith, U. (2007) Inflamed adipose tissue. A culprit underlying the metabolic syndrome and atherosclerosis. Atheroscler Thromb Vasc Biol27: 2276-2283.
15.
Hecht, H.S. (2008) The deadly double standard (the saga of screening for subclinical atherosclerosis). Am J Cardiol101: 1805-1807.
16.
Hlatky, M.A. (2008) Expanding the orbit of primary prevention - moving beyond Jupiter. N Engl J Med359: 2280-2282.
17.
Kannel, W.B., Dawber, T.R., Kagan, A., Revotskie, N. and Stokes, J. (1961) Factors of risk in development of coronary heart disease: six year follow-up experience. The Framingham Study. Ann Intern Med55: 35-50.
18.
Koenig, W. (2001) C-reactive protein and cardiovascular risk: has the time come for screening the general population? Clin Chem47: 1-2.
19.
Kushner, I., Rzewnicki, D. and Samols, D. (2006) What does minor elevation of C-reactive protein signify? Am J Med119: e17-e28.
20.
Lakoski, S.G., Greenland, P., Wong, N.D., Schreiner, P.J., Herrington, D.M., Kronmal, R.A. et al. (2007) Coronary artery calcium scores and risk for cardiovascular events in women classified as `low risk' based on Framingham risk score. The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med167: 2437-2445.
21.
Liao, J.K. (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest110: 285-288.
22.
Mora, S. and Ridker, P.M. (2006) Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention?Am J Cardiol97(Suppl.): 33A-41A.
23.
Packard, R.R.S. and Libby, P. (2008) Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem54: 24-38.
24.
Pearson, T.A., Mensah, G.A., Alexander, R.W., Anderson, J.L., Richard, O., Cannon, III. R.O., Criqui, M. et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers of Disease Control and Prevention and the American Heart Association. Circulation107: 499-511.
25.
Pierre-Paul, D. and Gahtan, V. (2003) Noncholesterollowering effects of statins. Vasc Endovascular Surg37: 301-313.
26.
Ridker, P.M. (2001) Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial . Eur Heart J22: 2135-2137.
27.
Ridker, P.M. (2003) Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Rationale and design of the JUPITER trial. Circulation108: 2292-2297.
28.
Ridker, P.M., Danielson, E., Fonseca, F.A.H., Jacques Genest, J., Antonio, M., Gotto Jr, A.M. et al. (2008a) for the JUPITER Study Group (2008a) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med359: 2195-2207.
29.
Ridker, P.M., Fonseca, F.A.H., Genest, J., Gotto, A.M., Kastelein, J.J.P., Khurmi, N.S. et al. (2007a) Baseline characteristics of participants in the JUPITER trial. a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol100: 1659-1664.
30.
Ridker, P.M., Paynter, N.P., Rifai, N., Gaziano, J.M. and Cook, N.R. (2008b) C-reactive protein and parental history improve global cardiovascular risk prediction. The Reynolds Risk Score for men. Circulation118: 2243-2251.
31.
Ridker, P.M., Wilson, P.W.F. and Grundy, S.M. (2004) Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation109: 2818-2825.
32.
Ridker, P.M., Buring, J.E., Rifai, N. and Cook, N.R. (2007b) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score. JAMA297: 611-619.
33.
Rifai, N. and Ridker, P.M. (2001) Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem47: 28-30.
34.
Shepherd, J., Vidt, D.G., Miller, E., Harris, S. and Blasetto, J. (2007) Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology107: 433-443.
35.
Ulrich, L. and Liao, J.K. (2003) Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep5: 372-378.
36.
van der Harst, P., Asselbergs, F.W., Hillege, H.L., Bakker, S.J.L., Voors, A.A., van Veldhuisen, D.J. et al. (2007) Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. Am J Cardiol100: 1548-1551.
37.
Wang, T.J., Gona, P., Larson, M.G., Tofler, G.H., Levy, D., Newton-Cheh, C. et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med355: 2631-2639.
38.
Ware, J.H. (2008) The limitations of risk factors as prognostic tools . N Engl J Med355: 2615-2617.
39.
Wilson, P.W.F. (2008) Cardiovascular risk assessment - where are we going . Preventive Cardiol11: 183-184.
40.
Wilson, P.W.F., Pencina, M., Jacques, P., Selhub, J., D'Agostino Sr, R. and O'Donnell, C.J. (2008) C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes1: 92-97.
41.
Yeh, E.T.H. and Palusinski, T.P. (2003) C-reactive protein: the pawn has been promoted to queen. Current Atheroscler Rep5: 101-105.
